Immunotherapy against EBV-lymphoma in recipients of HSCT.
Epstein-Barr virus (EBV)-associated lymphoproliferations represent life-threatening complications of hematopoietic stem cell transplantation. In the last decade, immunological therapeutic strategies that allow us to selectively abrogate the origin of lymphoproliferation, namely B-cell compartment or EBV antigen-expressing tumor cells, have significantly reduced treatment-related toxicity while maintaining equal or superior efficacy. A further implementation is the possibility of preventing disease occurrence by delivering immunotherapy in the presymptomatic phase, on the basis of EBV-DNA blood levels. Despite the excellent results, T-cell therapy with EBV-specific cytotoxic T-lymphocytes has but a marginal role in the treatment of these forms. Promising implementations are underway, including logistic solutions to extend T-cell therapy beyond academic centers, delineation of strategies aimed at simplifying/shortening production and targeting immune evasion mechanisms exerted by tumor cells.